Lupus is more than a rash. It is an autoimmune disorder where antibodies attack healthy tissues across organs. Damage can begin years before symptoms, which is why early immune balance and organ support matter.
SLE occurs when your body produces antibodies that mistakenly target your own tissues. This can affect kidneys, heart, lungs, brain, and joints at the same time.
The concerning reality is that disease-related antibodies may appear years before symptoms emerge, causing silent organ damage. Over 200,000 Americans have lupus, making it more common than multiple sclerosis.
Why this matters
Early modulation may help protect organs while standard care manages flares.
• Extreme fatigue unrelieved by rest • Multi-joint pain • Photosensitive skin rash (butterfly rash in ~50%)
• Lupus nephritis (~60% within 5 years) • Cardiovascular disease • Neurological problems
• 30–50% risk of irreversible organ damage by 10 years • Episodic flares can mask damage accumulation
Conventional treatment relies on corticosteroids, hydroxychloroquine, and immunosuppressants to reduce inflammation by broadly suppressing immune activity.
Only 30 to 40 percent respond adequately to newer biologics, and around 20 percent remain refractory to conventional treatments. Long-term steroid use can cause serious complications such as osteoporosis, infection risk, and metabolic problems.
These medications suppress symptoms rather than restore immune balance. Organ damage can continue despite control of flares.
Aim to restore immune balance rather than only suppress it. MSCs can modulate multiple immune cells and secrete factors that calm inflammation while supporting repair.
MSCs increase Tregs and modulate B cells and dendritic cells, helping reduce harmful autoantibody activity while preserving protective immunity.
Cells migrate to inflamed organs and release factors such as TGF-beta and TSG-6 that down‑regulate specific inflammatory pathways.
Sun 2010: severe, refractory SLE showed SLEDAI and renal improvements using umbilical cord MSCs. 2014 multicenter (n=40): 92.5% survival, 32.5% major and 27.5% partial clinical response at 12 months. 2024 work reports Treg/Th17 rebalancing and reduced neutrophil infiltration in nephritis.
Arc depends on organ involvement, severity, and adherence to care.
MSC therapy has shown a favorable safety profile in published studies. The 2014 multicenter trial reported 92.5% overall survival with no transplantation-related serious adverse events. Using umbilical cord-derived MSCs minimizes rejection risk.
Review organ involvement, disease activity, and prior therapies; align goals with your rheumatology team.
Outpatient IV infusions (commonly 2 sessions within one week) using umbilical cord-derived MSCs per protocol.
Monitor symptoms and markers (SLEDAI, proteinuria, complements) and adjust plan; consider retreatment if relapse occurs.
Interested in exploring whether MSC therapy might be appropriate for your lupus?
Our consultation evaluates your disease severity, current treatments, prior treatment responses, and candidacy for regenerative approaches.
Take the next step toward enhancing your stroke recovery through regenerative medicine.
Please bring (If available): Recent lab results including ANA and kidney function tests, current medication list, lupus activity records.
Online Booking Available